Brief: Gritstone Bio And The National Cancer Institute (Nci) Establish A Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination

Gritstone bio

14/02/2023 12:53

Feb 14 (Reuters) - Gritstone bio Inc  GRTS.O :
    * GRITSTONE BIO AND THE NATIONAL CANCER INSTITUTE (NCI)
ESTABLISH
A CLINICAL TRIAL AGREEMENT TO EVALUATE A NEOANTIGEN CELL
THERAPY-VACCINE COMBINATION
    * GRITSTONE BIO INC - HAS ENTERED INTO A CLINICAL TRIAL
AGREEMENT
WITH NATIONAL CANCER INSTITUTE
    * GRITSTONE BIO INC -  UNDER TERMS OF AGREEMENT NCI WILL
IDENTIFY
PATIENTS WITH METASTATIC CANCER THAT ARE ELIGIBLE FOR ADOPTIVE
CELL TRANSFER
    * GRITSTONE BIO INC - GRITSTONE WILL PROVIDE SLATE-KRAS
VACCINE AS
REQUESTED BY NCI FOR TRIAL
    * GRITSTONE BIO INC - EXPECTS TO INITIATE THIS SEPARATE,
RANDOMIZED STUDY IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX4Txwv2 
Further company coverage:  GRTS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))